Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

August 21, 2015

The MEDCAC panel opened the floor for public comments and then voted on five questions about Provenge. (For example: "How confident are you that there is adequate evidence to conclude that (Provenge) significantly improves overall survival in patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer?). In the end, the panel decided to give the vaccine its endorsement.

"Even though this is great news, I believe the panel chairman tried to downplay some solid support for Provenge by saying that the evidence needed to be 'broader and deeper,' when there is clearly more than a fair amount of confidence in the vaccine," said Kevin Johnson, ZERO's Senior Vice President of Government Relations and Advocacy who attended the MEDCAC meeting. "We need to continue to push the government on men's health issues like this, and we need to ensure all men have access to preventive services and testing."

Experts say a decision on whether Medicare will pay for Provenge should be made in several months.

SOURCE ZERO - The Project to End Prostate Cancer